Skip to content
sellModerate cluster of 2

Aaron G.L. Fletcher sold $208k of LTRN

owner at Lantern Pharma Inc.. 61,613 shares at an average of $3.38, traded Jun 10, 2025, filed Jun 13, 2025.

Warning score
42
Value
$208k
61,613 shares
Holdings after
118,626
-30% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    10% owner
    +12
  • Trade size
    $208k at market
    +12
  • Share of holdings sold
    Sold 30% of holdings
    +10
  • Cluster
    2 insiders selling within 14 days
    +8

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

LTRNOct 9, 2026 · close 0.81
Since filing Jun 13, 2025: -73.3%SPY +32.6% · excess -105.9%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001104659-25-059106, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jun 10, 2025SOpen-market sale
Common Stockindirect: By Bios Fund I QP, LP
-3$3.40$10207,419Jun 13, 2025
Jun 11, 2025SOpen-market sale
Common Stockindirect: By Bios Fund I QP, LP
-171$3.40$581207,248Jun 13, 2025
Jun 12, 2025SOpen-market sale
Common Stockindirect: By Bios Fund I QP, LP
-10,925$3.38$37k196,323Jun 13, 2025
Jun 10, 2025SOpen-market sale
Common Stockindirect: By Bios Fund I, LP
-5$3.40$17354,625Jun 13, 2025
Jun 11, 2025SOpen-market sale
Common Stockindirect: By Bios Fund I, LP
-293$3.40$996354,332Jun 13, 2025
Jun 12, 2025SOpen-market sale
Common Stockindirect: By Bios Fund I, LP
-18,678$3.38$63k335,654Jun 13, 2025
Jun 10, 2025SOpen-market sale
Common Stockindirect: By Bios Fund II NT, LP
-1$3.40$354,791Jun 13, 2025
Jun 11, 2025SOpen-market sale
Common Stockindirect: By Bios Fund II NT, LP
-45$3.40$15354,746Jun 13, 2025
Jun 12, 2025SOpen-market sale
Common Stockindirect: By Bios Fund II NT, LP
-2,886$3.38$9,75551,860Jun 13, 2025
Jun 10, 2025SOpen-market sale
Common Stockindirect: By Bios Fund II QP, LP
-5$3.40$17409,291Jun 13, 2025
Jun 11, 2025SOpen-market sale
Common Stockindirect: By Bios Fund II QP, LP
-338$3.40$1,149408,953Jun 13, 2025
Jun 12, 2025SOpen-market sale
Common Stockindirect: By Bios Fund II QP, LP
-21,557$3.38$73k387,396Jun 13, 2025
Jun 10, 2025SOpen-market sale
Common Stockindirect: By Bios Fund II, LP
-2$3.40$7125,330Jun 13, 2025
Jun 11, 2025SOpen-market sale
Common Stockindirect: By Bios Fund II, LP
-103$3.40$350125,227Jun 13, 2025
Jun 12, 2025SOpen-market sale
Common Stockindirect: By Bios Fund II, LP
-6,601$3.38$22k118,626Jun 13, 2025

Related signals

Other insiders at Lantern Pharma Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
35Weak
LTRNsell 2
Lantern Pharma Inc.
Aaron G.L. Fletcher
owner
$124k
40,000 shares
-20%
42Moderate
LTRNsell 2
Lantern Pharma Inc.
Leslie W. Kreis
owner
$208k
61,613 shares
-30%
35Weak
LTRNsell 2
Lantern Pharma Inc.
Leslie W. Kreis
owner
$124k
40,000 shares
-20%
41Moderate
LTRNsell 2
Lantern Pharma Inc.
Aaron G.L. Fletcher
owner
$168k
56,237 shares
-26%
41Moderate
LTRNsell 2
Lantern Pharma Inc.
Leslie W. Kreis
owner
$168k
56,237 shares
-26%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Aaron G.L. Fletcher sold $208k of LTRN | InsiderTell